title: The effects of canrenone on inflammatory markers in patients with metabolic syndrome.
abstract: OBJECTIVE
  To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome.
  
  
  METHODS
  A total of 156 Caucasian patients were treated with placebo or canrenone, 50 mg once a day, for 3 months and then 50 mg twice a day, till the end of the study. We evaluated: systolic (SBP) and diastolic blood pressure (DBP), body weight, body mass index (BMI), fasting plasma glucose (FPG), lipid profile, plasma aldosterone, creatinine, potassium, brain natriuretic peptide (BNP), metalloproteinases 2 and 9 (MMP-2 and -9), lipoprotein (a) (Lp(a)), and serum myeloperoxidase (MPO).
  
  
  RESULTS
  We observed a significant decrease of SBP and DBP in the canrenone group compared to baseline. Canrenone gave a significant decrease of MMP-2 and -9, Lp(a), and MPO compared to baseline, not observed with placebo. Plasma aldosterone, but not BNP, decreased with canrenone, both compared to baseline and to placebo.
  
  
  CONCLUSIONS
  Canrenone seems to be effective in reducing blood pressure in patients with metabolic syndrome. Moreover, canrenone seems also to improve MPO, Lp(a), and metalloproteinases in these patients.
authors.affiliation: Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S. Matteo , Pavia , Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Derosa
authors.forename: Davide
authors.initials: D
authors.lastname: Romano
authors.forename: Lucio
authors.initials: L
authors.lastname: Bianchi
authors.forename: Angela
authors.initials: A
authors.lastname: D'Angelo
authors.forename: Pamela
authors.initials: P
authors.lastname: Maffioli
mesh_terms: D000368:Aged; D000450:Aldosterone / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D002192:Canrenone / Q000627:therapeutic use*; D003401:Creatine / Q000097:blood; D004311:Double-Blind Method; D005215:Fasting / Q000097:blood; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000188:drug therapy*; D045726:Metalloproteases / Q000097:blood; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D009195:Peroxidase / Q000097:blood; D011188:Potassium / Q000097:blood; D044465:White People
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D008055:Lipids; D008074:Lipoproteins; D020097:Natriuretic Peptide, Brain; D000450:Aldosterone; D002192:Canrenone; D009195:Peroxidase; D045726:Metalloproteases; D003401:Creatine; D011188:Potassium
keywords: Canrenone; inflammatory markers; metalloproteinases